United Therapeutics Corporation (NASDAQ:UTHR – Free Report) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for United Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will post earnings per share of $27.39 for the year, up from their previous estimate of $25.23. HC Wainwright has a “Buy” rating and a $660.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q4 2026 earnings at $7.12 EPS, FY2027 earnings at $39.79 EPS, FY2028 earnings at $39.83 EPS, FY2029 earnings at $41.54 EPS and FY2030 earnings at $47.58 EPS.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $6.19 EPS.
Check Out Our Latest Stock Analysis on UTHR
United Therapeutics Stock Performance
Shares of UTHR stock opened at $564.81 on Friday. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $607.89. The stock has a market cap of $24.76 billion, a P/E ratio of 20.24, a P/E/G ratio of 1.63 and a beta of 0.75. The company has a 50 day simple moving average of $506.70 and a two-hundred day simple moving average of $479.24.
Insider Transactions at United Therapeutics
In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $581.63, for a total value of $5,525,485.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $23,563,576.19. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $11,196,676.92. This represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 361,820 shares of company stock valued at $182,730,910 over the last three months. Corporate insiders own 10.30% of the company’s stock.
Institutional Trading of United Therapeutics
Several institutional investors have recently made changes to their positions in the business. Clearstead Advisors LLC lifted its holdings in United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 23 shares in the last quarter. Independent Advisor Alliance grew its holdings in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares in the last quarter. Bessemer Group Inc. grew its holdings in United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after buying an additional 28 shares in the last quarter. Florida Financial Advisors LLC raised its position in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 28 shares during the last quarter. Finally, NDVR Inc. raised its position in shares of United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.
Trending Headlines about United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: Positive Phase‑3 Tyvaso (IPF) data — the trial met its primary endpoint, supporting potential near‑term revenue upside from an expanded label and underpinning recent optimism. United Therapeutics reports positive results for lung drug
- Positive Sentiment: HC Wainwright raised price target and lifted multi‑year EPS forecasts (now Buy, $660 PT) and other brokers have moved targets higher — analyst upgrades increase buy-side conviction and support a higher valuation range. United Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
- Positive Sentiment: Strong earnings‑surprise history and bullish earnings outlook — coverage notes (e.g., Zacks) highlight United Therapeutics’ track record of beating estimates, increasing the probability of another upside surprise at the next report. Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
- Neutral Sentiment: Elevated options activity — traders are positioning around the clinical news and upcoming earnings, which can amplify intraday volatility but is not a direct fundamental change. United Therapeutics Target of Unusually High Options Trading
- Neutral Sentiment: Coverage/valuation pieces and peer comparisons are proliferating — these shape expectations for how Tyvaso lifts long‑term value but won’t themselves change fundamentals. (See Zacks comparison with Catalyst (CPRX) and valuation write‑ups.) CPRX or UTHR: Which Is the Better Value Stock Right Now?
- Negative Sentiment: Insider selling by senior executives (CEO, EVP, CFO) — multi‑million dollar disposals under 10b5‑1 plans may be read as profit‑taking and can add short‑term selling pressure despite being pre‑arranged. Rothblatt SEC Filing (Example)
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
